On 28 MAY Xencor Inc (NASDAQ:XNCR) announced that the first subject has been dosed in a Phase 1a clinical trial of XmAb 7195. XmAb 7195 is a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and other atopic disease. Xencor Inc (NASDAQ:XNCR) weekly performance is 11.89%. On last trading day company shares ended up $11.39. Analysts mean target price for the company is $16.33. Xencor Inc (NASDAQ:XNCR) distance from 50-day simple moving average (SMA50) is 20.67%.
On 11 JUNE Applied Genetic Technologies Corp (NASDAQ:AGTC) reported ($25.45) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.37) by $25.08. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.15 million. Analysts expect that Applied Genetic Technologies Corp will post $-14.11 EPS for the current fiscal year. Applied Genetic Technologies Corp (NASDAQ:AGTC) shares advanced 6.26% in last trading session and ended the day on $27.49. AGTC return on assets is -60.40%.
On 10 JUNE Idenix Pharmaceuticals Inc (NASDAQ:IDIX) said it will be acquired by pharma giant, Merck. Merck’s offer price of $24.50 per share in cash was more than three times the company’s share price before the offer was announced. The acquisition, slated to close in the third quarter, is valued at about $3.85 billion. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares moved up 0.17% in last trading session and was closed at $23.64, while trading in range of $23.57 – $23.69. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) year to date (YTD) performance is 295.32%.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) said it was a big mover last session, as its shares rose. The rise came on solid volume too with far more shares changing hands than in a normal session. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) ended the last trading day at $6.05. Company weekly volatility is calculated as 5.97% and price to cash ratio as 5.15. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) showed a positive weekly performance of 15.24%.
On 30 MAY Agenus Inc (NASDAQ:AGEN) announced that Robert Stein, MD, PhD, the company’s Chief Scientific Officer, is scheduled to present a company overview at the Jefferies 2014 Global Healthcare Conference in New York City. Agenus Inc (NASDAQ:AGEN) weekly performance is 10.03%. On last trading day company shares ended up $3.51. Analysts mean target price for the company is $7.00. Agenus Inc (NASDAQ:AGEN) distance from 50-day simple moving average (SMA50) is 24.71%.